AstraZeneca Settles Patent Litigation for Ultomiris with $775 Million Payment

• (PLX AI) - AstraZeneca announces settlement of patent litigation for Ultomiris.
• • AstraZeneca says agreement with Chugai Pharmaceutical resolving all patent disputes
• • Under the terms of the agreement, Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022
• • No further amounts are payable by either party
• • The settlement does not impact AstraZeneca's financial guidance for 2022